FDA Issues MDO Orders for Over 6,500 E-Cigarette Products

May.15.2023
FDA Issues MDO Orders for Over 6,500 E-Cigarette Products
FDA issued marketing denial orders to 10 companies, preventing them from selling about 6,500 flavored e-cigarette products in the US.

On May 12th, the US Food and Drug Administration (FDA) issued marketing denial orders (MDOs) to 10 companies, all of which produced and sold approximately 6,500 flavors of e-cigarette oil and vape products. The MDOs prohibit these companies from marketing or distributing these products in the US, and retailers selling these illegal products will face enforcement actions from the FDA.


The tobacco products they submitted for pre-market tobacco product applications (PMTA) included a variety of flavored e-cigarette products, but they failed to provide sufficient evidence that allowing the sale of these products would meet public health protection requirements. The flavors of the products that were denied included citrus, strawberry cheesecake, cool mint, and mint.


Today's actions furthered the FDA's continued progress in reviewing and making decisions on over 26 million new tobacco product applications received since spring 2020, with a majority being for electronic cigarette products. Thus far, the FDA has completed reviews for 99% of these products.


Dr. Matthew Farrelly, director of the Office of Science at the FDA's Center for Tobacco Products (CTP), stated that...


Science is the cornerstone of the FDA's tobacco product review process. Today's decision to reject nearly 6,500 products was based on a lack of scientific evidence in the applications. We will continue to ensure that all new tobacco products undergo rigorous, scientific pre-market evaluations to determine whether they meet appropriate public health standards for legal marketing.


The FDA evaluates PMTAs based on public health standards, taking into account the risks and benefits to the entire population. When reviewing PMTAs for these companies, the premise is whether the products have additional advantages for adult smokers compared to tobacco flavors.


However, the evidence submitted by these applicants was insufficient to prove the existence of such advantages, hence they have received a marketing rejection order.


Brian King, the director of CTP, stated:


The applicant is responsible for providing sufficient scientific evidence to demonstrate that the introduction of a new tobacco product to the market meets the requirements for public health protection. To date, including the product in question, no flavored electronic cigarette products have met the standard for scientific adequacy. However, if the applicant meets this standard, the FDA will approve the product.


The companies that have obtained a marketing rejection order include:


Imperial Vapors LLC, Savage Enterprises, Big Time Vapes, SWT Global Supply Inc., Great Lakes Vapor, DNA Enterprise LLC doing business as Mech Sauce, and Absolute Vapor Inc., and ECBlend LLC are among the companies in the vaping industry. However, two other companies' names are not being disclosed by the FDA in order to protect potential commercial confidential information (CCI).


The FDA is committed to ensuring that all members of the industry, including manufacturers, importers, distributors and retailers, comply with the law.


Tobacco products that have been denied approval are prohibited from being sold, distributed, or marketed in the United States. They cannot be introduced or placed in interstate commerce, and if the product is already on the market, it must be removed or face enforcement action.


Reference:


The Food and Drug Administration (FDA) has issued orders denying marketing requests for around 6,500 flavored e-cigarette products.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | VELO Launches Tomorrowland Limited Edition 2026 as Festival IP Enters Nicotine Pouch Packaging
Product | VELO Launches Tomorrowland Limited Edition 2026 as Festival IP Enters Nicotine Pouch Packaging
BAT’s nicotine pouch brand VELO has introduced the Tomorrowland Limited Edition 2026. Public retail-channel information shows the product has appeared across multiple European online platforms, while Haypp UK has listed related SKUs with a “Coming soon” status. The packaging carries the wording “Official Tomorrowland Partner,” indicating that the collection is part of VELO’s official collaboration with the electronic music festival brand.
Jul.02
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Dick Durbin on May 13 criticized the Trump Administration’s Food and Drug Administration for approving the sale and marketing of fruit-flavored e-cigarettes for the first time, while also allowing some illegal vaping products to remain on the market. He also linked the regulatory shift to the departure of FDA Commissioner Marty Makary, saying White House pressure on regulators to approve tobacco product applications could create serious public-health consequences.
Regulations
May.15
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
New Canadian research shows that 34.8% of people aged 17 to 27 have tried nicotine pouches, up more than fourfold from 7.6% in 2022. The findings come as Conservative politicians, Alberta’s government and the tobacco industry push Ottawa to relax current restrictions on pouch sales.
Jun.12
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
U.S. vape company Charlie’s Holdings announced plans to pilot its age-gated flavored disposable vape products in hundreds of retail stores during the third quarter of 2026. The company said the products will utilize AI- and blockchain-powered age-verification technology designed to address FDA concerns over youth access and potentially create a new compliance pathway for flavored vape products.
Jun.15
 BAT Raises Growth Outlook for Smokeless Products as Velo and Vuse Gain Momentum
BAT Raises Growth Outlook for Smokeless Products as Velo and Vuse Gain Momentum
British American Tobacco (BAT) has raised its growth outlook for smokeless products, forecasting “mid-teens” growth for its new category portfolio, including vaping and nicotine pouch products, while global cigarette volumes are expected to decline further.
BAT
Jun.02